Mortality and morbidity in transsexual subjects treated with cross-sex hormones
- PMID: 9373456
- DOI: 10.1046/j.1365-2265.1997.2601068.x
Mortality and morbidity in transsexual subjects treated with cross-sex hormones
Abstract
Objective: The optimum steroid hormone treatment regimes for transsexual subjects has not yet been established. We have investigated the mortality and morbidity figures in a large group of transsexual subjects receiving cross-sex hormone treatment.
Design: A retrospective, descriptive study in a university teaching hospital.
Subjects: Eight hundred and sixteen male-to-female (M-->F) and 293 female-to-male (F-->M) transsexuals.
Interventions: Subjects had been treated with cross-sex hormones for a total of 10,152 patient-years.
Outcome measures: Standardized mortality and incidence ratios were calculated from the general Dutch population (age- and gender-adjusted) and were also compared to side effects of cross-sex hormones in transsexuals reported in the literature.
Results: In both the M-->F and F-->M transsexuals, total mortality was not higher than in the general population and, largely, the observed mortality could not be related to hormone treatment. Venous thromboembolism was the major complication in M-->F transsexuals treated with oral oestrogens and anti-androgens, but fewer cases were observed since the introduction of transdermal oestradiol in the treatment of transsexuals over 40 years of age. No cases of breast carcinoma but one case of prostatic carcinoma were encountered in our population. No serious morbidity was observed which could be related to androgen treatment in the F-->M transsexuals.
Conclusion: Mortality in male-to-female and female-to-male transsexuals is not increased during cross-sex hormone treatment. Transdermal oestradiol administration is recommended in male-to-female transsexuals, particularly in the population over 40 years in whom a high incidence of venous thromboembolism was observed with oral oestrogens. It seems that in view of the deep psychological needs of transsexuals to undergo sex reassignment, our treatment schedule of cross-sex hormone administration is acceptably safe.
Similar articles
-
A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones.Eur J Endocrinol. 2011 Apr;164(4):635-42. doi: 10.1530/EJE-10-1038. Epub 2011 Jan 25. Eur J Endocrinol. 2011. PMID: 21266549
-
Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience.J Clin Endocrinol Metab. 2008 Jan;93(1):19-25. doi: 10.1210/jc.2007-1809. Epub 2007 Nov 6. J Clin Endocrinol Metab. 2008. PMID: 17986639 Review.
-
Venous thrombosis and changes of hemostatic variables during cross-sex hormone treatment in transsexual people.J Clin Endocrinol Metab. 2003 Dec;88(12):5723-9. doi: 10.1210/jc.2003-030520. J Clin Endocrinol Metab. 2003. PMID: 14671159
-
Differential effects of cross-sex hormonal treatment on plasma asymmetric dimethylarginine (ADMA) in healthy male-to-female and female-to-male transsexuals.Atherosclerosis. 2009 Sep;206(1):245-50. doi: 10.1016/j.atherosclerosis.2009.01.020. Epub 2009 Jan 24. Atherosclerosis. 2009. PMID: 19324362
-
Venous thrombo-embolism as a complication of cross-sex hormone treatment of male-to-female transsexual subjects: a review.Andrologia. 2014 Sep;46(7):791-5. doi: 10.1111/and.12150. Epub 2013 Aug 15. Andrologia. 2014. PMID: 23944849 Review.
Cited by
-
Changes in Blood Lipids Following Initiation of Gender Affirming Hormone Therapy: A Systematic Review and Meta-Analysis.J Clin Transl Endocrinol. 2024 Apr 30;36:100349. doi: 10.1016/j.jcte.2024.100349. eCollection 2024 Jun. J Clin Transl Endocrinol. 2024. PMID: 38737626 Free PMC article.
-
Estrogen's sex-specific effects on ischemic cell death and estrogen receptor mRNA expression in rat cortical organotypic explants.Aging Brain. 2024 Apr 16;5:100117. doi: 10.1016/j.nbas.2024.100117. eCollection 2024. Aging Brain. 2024. PMID: 38650743 Free PMC article.
-
All-cause and suicide mortalities among adolescents and young adults who contacted specialised gender identity services in Finland in 1996-2019: a register study.BMJ Ment Health. 2024 Feb 17;27(1):e300940. doi: 10.1136/bmjment-2023-300940. BMJ Ment Health. 2024. PMID: 38367979 Free PMC article.
-
Considerations for Gender-Affirming Hormonal and Surgical Care Among Transgender and Gender Diverse Adolescents and Adults With Congenital Heart Disease.J Am Heart Assoc. 2024 Feb 6;13(3):e031004. doi: 10.1161/JAHA.123.031004. Epub 2024 Jan 31. J Am Heart Assoc. 2024. PMID: 38293963 Free PMC article.
-
Exploring Hormone Therapy Effects on Reproduction and Health in Transgender Individuals.Medicina (Kaunas). 2023 Nov 29;59(12):2094. doi: 10.3390/medicina59122094. Medicina (Kaunas). 2023. PMID: 38138197 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources